SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is experiencing significant momentum driven by high-stakes buyout speculation and anticipation of the 80th clinical event from its REGAL Phase 3 trial. The community is actively debating the potential for a curative AML treatment while short-covering dynamics and institutional accumulation fuel a volatile, upward trending environment.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as investors react to a major divestment of its gaming arm and reports that its open-source AI models have significantly outperformed Western peers in download volume. The community is actively debating the company's aggressive pivot toward AI infrastructure and cloud growth, while some remain skeptical of the share dilution and broader risks associated with Chinese equity markets.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as investors react to a significant expansion of its custom AI chip partnership with Google, which includes a substantial warrant deal. While the announcement spurred bullish sentiment regarding long-term AI revenue potential, the stock is also facing volatility as traders weigh the implications of potential share dilution and customer concentration.

TOSHI

TOSHI is trending as community members closely monitor order books for signs of a potential short squeeze, with many users expressing optimism that the asset is bottoming out and preparing for a significant rally. Despite frustration over price volatility, long-term holders continue to emphasize their conviction and remain focused on future catalysts like potential exchange listings.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors await a definitive FDA decision or PDUFA extension following the conclusion of the August 22 target date. The community is sharply divided between bulls citing institutional accumulation and the potential for a regulatory path forward for deramiocel, and bears pointing to a recent activist letter raising cash-burn concerns and the lack of official news.

Ethena

Ethena (ENA) is capturing significant attention as investors react to institutional validation, including recent capital raises and strategic partnerships, while the community closely watches for potential price breakouts amidst a broader altcoin market shift.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is surging amid widespread speculation regarding potential buyout interest from a large biopharma company, with investors closely watching the commercial momentum of Briumvi and upcoming subcutaneous formulation data as primary value drivers. The community remains hyper-focused on the company's valuation potential and the strategic necessity for larger pharma players to secure high-growth assets to offset upcoming patent cliffs.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant attention as community sentiment shifts aggressively bullish, fueled by massive institutional ETF inflows and heavy short liquidations that are pushing prices toward key resistance levels. Traders are actively debating whether the current momentum will lead to a sustained breakout past resistance or a temporary consolidation before the next leg higher.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing heavy volatility and downward pressure as investors react to a new $600 million at-the-market equity offering, fueling widespread concerns about shareholder dilution. While some traders view the capital raise as a necessary step to fund capacity expansion for the AI-driven data center market, many in the community remain skeptical, criticizing the timing of the after-hours announcement.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

SQD is trending as the community debates its utility as a blockchain data infrastructure project and its connection to Rezolve AI, with some users highlighting its network scaling potential while others voice skepticism regarding its price performance. Discussions focus on its role in indexing data for AI and DeFi applications compared to competitors, with persistent debates over whether it functions as a long-term infrastructure asset or a transactional utility coin.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Kyntra Bio Q2 2026 Earnings Call: Complete Transcript

On Thursday, Kyntra Bio (NASDAQ:KYNB) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
Benzinga APIs provide real-time access to earnings call transcripts andread more...

Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates

Kyntra Bio (KYNB) delivered earnings and revenue surprises of -47.17% and -173.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates

Kamada (KMDA) delivered earnings and revenue surprises of +33.33% and +6.39%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?

Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates

Vericel (VCEL) delivered earnings and revenue surprises of +200.00% and +7.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of +56.67% and +5.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Kyntra Bio (KYNB) Q1 2026 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates

Kyntra Bio (KYNB) delivered earnings and revenue surprises of -11.48% and +140.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -4.60% and +52.44%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Kyntra Bio Inc.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$3.66	--	--	N/A
Q2 '26	$2.96	$2.96	--	EXPECTED
Q1 '26	-$3.36	-$3.76	-12.07%	MISSED
Q4 '25	-$3.88	-$3.51	9.65%	BEAT
Q3 '25	-$4.01	$49.61	1338.08%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings